Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV

Kathleen Squires, Adriano Lazzarin, José M. Gatell, William G. Powderly, Vadim Pokrovskiy, Jean François Delfraissy, Joseph Jemsek, Antonio Rivero, Willy Rozenbaum, Shannon Schrader, Michael Sension, Asda Vibhagool, Alexandra Thiry, Michael Giordano

Research output: Contribution to journalArticle

276 Citations (Scopus)

Abstract

Background: Atazanavir, an azapeptide protease inhibitor (PI), has pharmacokinetics that allow once-daily dosing, and it is not associated with significant PI-associated dyslipidemia. Methods: A randomized, double-blind, double-dummy, active-controlled, 2-arm study comparing the antiviral efficacy and safety of atazanavir 400 mg administered once daily with efavirenz 600 mg administered once daily in combination with open-label fixed-dose zidovudine plus lamivudine twice daily. The 810 treatment-naive patients were stratified by HIV RNA level. The primary efficacy end point was the proportion of treated patients with HIV RNA levels + cell counts increased at comparable magnitudes and rates in the 2 treatment arms (mean change at week 48: 176 cells/mm3 with atazanavir, 160 cells/mm3 with efavirenz). Atazanavir-treated patients relative to comparator-treated patients did not demonstrate significant increases in total cholesterol, fasting low-density lipoprotein cholesterol, or fasting triglycerides over 48 weeks of therapy. Atazanavir-linked bilirubin elevations infrequently resulted in treatment discontinuation (

Original languageEnglish
Pages (from-to)1011-1019
Number of pages9
JournalJournal of Acquired Immune Deficiency Syndromes
Volume36
Issue number5
DOIs
Publication statusPublished - Aug 15 2004

Fingerprint

efavirenz
Lamivudine
Zidovudine
HIV
Protease Inhibitors
Fasting
RNA
Therapeutics
Dyslipidemias
Bilirubin
LDL Cholesterol
Antiviral Agents
Triglycerides
Pharmacokinetics
Cell Count
Cholesterol
Atazanavir Sulfate
Safety

Keywords

  • Atazanavir
  • Efavirenz
  • Highly active antiretroviral therapy
  • HIV
  • Lipids
  • Protease inhibitors

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. / Squires, Kathleen; Lazzarin, Adriano; Gatell, José M.; Powderly, William G.; Pokrovskiy, Vadim; Delfraissy, Jean François; Jemsek, Joseph; Rivero, Antonio; Rozenbaum, Willy; Schrader, Shannon; Sension, Michael; Vibhagool, Asda; Thiry, Alexandra; Giordano, Michael.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 36, No. 5, 15.08.2004, p. 1011-1019.

Research output: Contribution to journalArticle

Squires, K, Lazzarin, A, Gatell, JM, Powderly, WG, Pokrovskiy, V, Delfraissy, JF, Jemsek, J, Rivero, A, Rozenbaum, W, Schrader, S, Sension, M, Vibhagool, A, Thiry, A & Giordano, M 2004, 'Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV', Journal of Acquired Immune Deficiency Syndromes, vol. 36, no. 5, pp. 1011-1019. https://doi.org/10.1097/00126334-200408150-00003
Squires, Kathleen ; Lazzarin, Adriano ; Gatell, José M. ; Powderly, William G. ; Pokrovskiy, Vadim ; Delfraissy, Jean François ; Jemsek, Joseph ; Rivero, Antonio ; Rozenbaum, Willy ; Schrader, Shannon ; Sension, Michael ; Vibhagool, Asda ; Thiry, Alexandra ; Giordano, Michael. / Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. In: Journal of Acquired Immune Deficiency Syndromes. 2004 ; Vol. 36, No. 5. pp. 1011-1019.
@article{02e6e1751b264f629b9e535c70083a48,
title = "Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV",
abstract = "Background: Atazanavir, an azapeptide protease inhibitor (PI), has pharmacokinetics that allow once-daily dosing, and it is not associated with significant PI-associated dyslipidemia. Methods: A randomized, double-blind, double-dummy, active-controlled, 2-arm study comparing the antiviral efficacy and safety of atazanavir 400 mg administered once daily with efavirenz 600 mg administered once daily in combination with open-label fixed-dose zidovudine plus lamivudine twice daily. The 810 treatment-naive patients were stratified by HIV RNA level. The primary efficacy end point was the proportion of treated patients with HIV RNA levels + cell counts increased at comparable magnitudes and rates in the 2 treatment arms (mean change at week 48: 176 cells/mm3 with atazanavir, 160 cells/mm3 with efavirenz). Atazanavir-treated patients relative to comparator-treated patients did not demonstrate significant increases in total cholesterol, fasting low-density lipoprotein cholesterol, or fasting triglycerides over 48 weeks of therapy. Atazanavir-linked bilirubin elevations infrequently resulted in treatment discontinuation (",
keywords = "Atazanavir, Efavirenz, Highly active antiretroviral therapy, HIV, Lipids, Protease inhibitors",
author = "Kathleen Squires and Adriano Lazzarin and Gatell, {Jos{\'e} M.} and Powderly, {William G.} and Vadim Pokrovskiy and Delfraissy, {Jean Fran{\cc}ois} and Joseph Jemsek and Antonio Rivero and Willy Rozenbaum and Shannon Schrader and Michael Sension and Asda Vibhagool and Alexandra Thiry and Michael Giordano",
year = "2004",
month = "8",
day = "15",
doi = "10.1097/00126334-200408150-00003",
language = "English",
volume = "36",
pages = "1011--1019",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV

AU - Squires, Kathleen

AU - Lazzarin, Adriano

AU - Gatell, José M.

AU - Powderly, William G.

AU - Pokrovskiy, Vadim

AU - Delfraissy, Jean François

AU - Jemsek, Joseph

AU - Rivero, Antonio

AU - Rozenbaum, Willy

AU - Schrader, Shannon

AU - Sension, Michael

AU - Vibhagool, Asda

AU - Thiry, Alexandra

AU - Giordano, Michael

PY - 2004/8/15

Y1 - 2004/8/15

N2 - Background: Atazanavir, an azapeptide protease inhibitor (PI), has pharmacokinetics that allow once-daily dosing, and it is not associated with significant PI-associated dyslipidemia. Methods: A randomized, double-blind, double-dummy, active-controlled, 2-arm study comparing the antiviral efficacy and safety of atazanavir 400 mg administered once daily with efavirenz 600 mg administered once daily in combination with open-label fixed-dose zidovudine plus lamivudine twice daily. The 810 treatment-naive patients were stratified by HIV RNA level. The primary efficacy end point was the proportion of treated patients with HIV RNA levels + cell counts increased at comparable magnitudes and rates in the 2 treatment arms (mean change at week 48: 176 cells/mm3 with atazanavir, 160 cells/mm3 with efavirenz). Atazanavir-treated patients relative to comparator-treated patients did not demonstrate significant increases in total cholesterol, fasting low-density lipoprotein cholesterol, or fasting triglycerides over 48 weeks of therapy. Atazanavir-linked bilirubin elevations infrequently resulted in treatment discontinuation (

AB - Background: Atazanavir, an azapeptide protease inhibitor (PI), has pharmacokinetics that allow once-daily dosing, and it is not associated with significant PI-associated dyslipidemia. Methods: A randomized, double-blind, double-dummy, active-controlled, 2-arm study comparing the antiviral efficacy and safety of atazanavir 400 mg administered once daily with efavirenz 600 mg administered once daily in combination with open-label fixed-dose zidovudine plus lamivudine twice daily. The 810 treatment-naive patients were stratified by HIV RNA level. The primary efficacy end point was the proportion of treated patients with HIV RNA levels + cell counts increased at comparable magnitudes and rates in the 2 treatment arms (mean change at week 48: 176 cells/mm3 with atazanavir, 160 cells/mm3 with efavirenz). Atazanavir-treated patients relative to comparator-treated patients did not demonstrate significant increases in total cholesterol, fasting low-density lipoprotein cholesterol, or fasting triglycerides over 48 weeks of therapy. Atazanavir-linked bilirubin elevations infrequently resulted in treatment discontinuation (

KW - Atazanavir

KW - Efavirenz

KW - Highly active antiretroviral therapy

KW - HIV

KW - Lipids

KW - Protease inhibitors

UR - http://www.scopus.com/inward/record.url?scp=3342924014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3342924014&partnerID=8YFLogxK

U2 - 10.1097/00126334-200408150-00003

DO - 10.1097/00126334-200408150-00003

M3 - Article

VL - 36

SP - 1011

EP - 1019

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 5

ER -